- Home
- STRO vs SER Comparison
STRO vs SER Comparison
Compare STRO & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- SER
- Stock Information
- Founded
- STRO 2003
- SER 2017
- Country
- STRO United States
- SER United States
- Employees
- STRO N/A
- SER N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- SER Health Care
- Exchange
- STRO Nasdaq
- SER Nasdaq
- Market Cap
- STRO 50.0M
- SER 53.5M
- IPO Year
- STRO 2018
- SER 2018
- Fundamental
- Price
- STRO $0.87
- SER $5.63
- Analyst Decision
- STRO Hold
- SER Strong Buy
- Analyst Count
- STRO 8
- SER 1
- Target Price
- STRO $6.14
- SER $11.00
- AVG Volume (30 Days)
- STRO 2.3M
- SER 10.2K
- Earning Date
- STRO 05-08-2025
- SER 05-08-2025
- Dividend Yield
- STRO N/A
- SER N/A
- EPS Growth
- STRO N/A
- SER N/A
- EPS
- STRO N/A
- SER N/A
- Revenue
- STRO $62,043,000.00
- SER $51,000.00
- Revenue This Year
- STRO N/A
- SER N/A
- Revenue Next Year
- STRO $1.29
- SER N/A
- P/E Ratio
- STRO N/A
- SER N/A
- Revenue Growth
- STRO N/A
- SER N/A
- 52 Week Low
- STRO $0.52
- SER $3.81
- 52 Week High
- STRO $5.17
- SER $14.57
- Technical
- Relative Strength Index (RSI)
- STRO 48.53
- SER 52.25
- Support Level
- STRO $0.80
- SER $5.27
- Resistance Level
- STRO $1.11
- SER $6.61
- Average True Range (ATR)
- STRO 0.18
- SER 0.51
- MACD
- STRO 0.02
- SER -0.03
- Stochastic Oscillator
- STRO 41.53
- SER 35.53
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.